Nuvectis Pharma (NVCT) Assets Average (2022 - 2026)

Nuvectis Pharma has reported Assets Average for 5 years, with the latest figure at $28.6 million in Q1 2026.

• Quarterly Assets Average rose 17.13% year-over-year to $28.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.6 million (up 17.13% YoY) and the FY2025 annual result came in at $25.2 million, up 33.14% from the prior year.
• Assets Average declined to $28.6 million in Q1 2026 per NVCT's latest filing, from $33.6 million in the prior quarter.
• Over five years, Assets Average peaked at $33.6 million in Q4 2025 and troughed at $12.1 million in Q1 2022.
• A 5-year average of $22.0 million and a median of $20.6 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2025: Assets Average fell 24.57% in 2024, then soared 87.38% in 2025.
• Over 5 years, Assets Average stood at $22.6 million in 2022, then declined by 8.45% to $20.7 million in 2023, then declined by 13.35% to $18.0 million in 2024, then jumped by 87.38% to $33.6 million in 2025, then retreated by 15.14% to $28.6 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $28.6 million, $33.6 million, and $31.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.